Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Operating Leases (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Operating Leases for 5 consecutive years, with $972000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases changed N/A to $972000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $972000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $972000.0 for FY2025, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $972000.0 at Actinium Pharmaceuticals, up from $531000.0 in the prior quarter.
  • The five-year high for Operating Leases was $2.2 million in Q3 2022, with the low at $62000.0 in Q2 2021.
  • Average Operating Leases over 5 years is $1.3 million, with a median of $1.3 million recorded in 2024.
  • The sharpest move saw Operating Leases changed 0.0% in 2024, then plummeted 57.22% in 2025.
  • Over 5 years, Operating Leases stood at $62000.0 in 2021, then surged by 3259.68% to $2.1 million in 2022, then decreased by 25.44% to $1.6 million in 2023, then decreased by 26.66% to $1.1 million in 2024, then dropped by 14.66% to $972000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $972000.0, $531000.0, and $685000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.